Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Canada Attempts Biosimilar Balancing Act

Executive Summary

Plans to make Canada’s biologics market more competitive for biosimilars are advancing as payers are planning consultations on how price negotiations for biosimilars and biologics will proceed.

Advertisement

Related Content

Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures
Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study
Canada Ups Pricing Pressure on Biosimilars And Originators

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register